Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs IART: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IART Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

IART Overall Winner 6-Pillar Tally: AHCO 2 – 4 IART Matrix Metrics: AHCO 2 – 8 IART

As of Nov 20, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IART carries 45.5/100 (HOLD) at $13.25 (5.6x Forward P/E, 9.9% operating margin).

  • Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IART is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs IART
AHCO NASDAQ
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
IART NASDAQ Head-to-Head Winner
Integra LifeSciences Holdings
Surgical & Medical Instruments & Apparatus
$13.25
-2.21% 1D
Market Cap $1.1B
TTM Revenue $1.66B
Forward P/E 5.6x
Beta / 30D Vol 1.54β · 60% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 43.0 Fund 53.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 45
RSI-14: 44.7 · SMA20: $13.61 · SMA50: $14.08

6-Pillar Scorecard Institutional Category Breakdown (AHCO 2 – 4 IART)

Columns: Metric · AHCO · IART
1. Valuation Multiples IART
Forward P/E 7.8x 5.6x
Trailing P/E 7.8x 79.7x
PEG Ratio N/M 0.71x
EV / Revenue 0.9x 0.6x
2. Growth & Scale AHCO
Revenue Growth (YoY) +10.9% +2.3%
Earnings Growth (YoY) +6.7% +0.4%
TTM Revenue (USD) $3.44B $1.66B
Market Cap $989.8M $1.1B
3. Profitability & Quality IART
Gross Margin 18.2% 55.5%
Operating Margin 3.8% 9.9%
Net Profit Margin -11.8% 0.8%
Return on Equity (ROE) -28.4% 1.2%
4. Balance Sheet & Cash Flow IART
Cash Generation (TTM) $82M $72M
Cash Flow Margin 2.4% 4.3%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $77M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 66.9% (12th %ile) 57.4% (16th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IART
OpEx & R&D Intensity 14.4% of Rev ($495M) 45.6% of Rev ($755M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (2) vs IART (8)
Institutional Metric AHCO IART Criterion Row Edge
Market Capitalization
Scale
$989.8M $1.1B Larger Scale IART
Trailing P/E Ratio
Valuation
7.8x 79.7x Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x 5.6x Lower Multiple IART
Revenue Growth (YoY)
Growth
+10.9% +2.3% Higher Growth AHCO
Operating Margin (TTM)
Profitability
3.8% 9.9% Higher Margin IART
Net Profit Margin
Profitability
-11.8% 0.8% Higher Margin IART
Return on Equity (ROE)
Capital Efficiency
-28.4% 1.2% Higher ROE IART
52-Week Range Position
Momentum
24% ($5–$13) 39% ($9–$20) Stronger Trend IART
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 1.54β · 60% Vol Lower Realized Risk IART
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite IART
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $1.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 55.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 0.71x PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) $72M ($77M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +9.18 pp
AHCO: +16.69% · IART: +7.51%
3M Horizon AHCO +48.5 pp
AHCO: +27.89% · IART: -20.61%
6M Horizon IART +18.85 pp
AHCO: -31.1% · IART: -12.25%
1Y Horizon IART +39.71 pp
AHCO: -20.88% · IART: +18.83%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue IART Revenue AHCO Op. Margin IART Op. Margin Margin Leader
FY2018 $350M $1.47B 9.0% 7.5% AHCO
FY2019 $530M $1.52B 5.5% 6.2% IART
FY2020 $1.06B $1.37B 6.8% 11.0% IART
FY2021 $2.45B $1.54B 9.2% 12.8% IART
FY2022 $2.97B $1.56B 6.4% 15.3% IART
FY2023 $3.20B $1.54B -18.7% 7.2% IART
FY2024 $3.26B $1.61B 8.1% 1.8% AHCO
FY2025 $3.24B $1.64B 2.8% -30.2% AHCO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IART BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 57.4%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IART Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
IART Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment 45.6% of Rev ($755M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs IART Key Questions & Quantitative Answers

As of Nov 20, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IART carries 45.5/100 (HOLD) at $13.25 (5.6x Forward P/E, 9.9% operating margin). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IART is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AHCO leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with IART at +2.3% YoY revenue growth and +0.4% YoY earnings growth on $1.66B TTM revenue (55.5% gross margin, 9.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while IART shifted +11.6%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 45.6% of Rev ($755M) (0 disclosures) for IART.

IART screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas IART trades at 5.6x Forward P/E, 79.7x Trailing P/E, 0.71x PEG, and 0.6x EV/Revenue (4.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus IART (1.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, IART carries 57.4% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.54β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.